Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation

Research output: Contribution to journalArticlepeer-review

Standard

Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation. / McCutcheon, Keir; Vanhaverbeke, Maarten; Dabin, Jérémie; Pauwels, Ruben; Schoonjans, Werner; Desmet, Walter ; Bennett, Johan.

In: Journal of Interventional Cardiology, Vol. 2021, 3146104, 14.12.2021, p. 1-4.

Research output: Contribution to journalArticlepeer-review

Harvard

McCutcheon, K, Vanhaverbeke, M, Dabin, J, Pauwels, R, Schoonjans, W, Desmet, W & Bennett, J 2021, 'Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation', Journal of Interventional Cardiology, vol. 2021, 3146104, pp. 1-4. https://doi.org/10.1155/2021/3146104

APA

McCutcheon, K., Vanhaverbeke, M., Dabin, J., Pauwels, R., Schoonjans, W., Desmet, W., & Bennett, J. (2021). Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation. Journal of Interventional Cardiology, 2021, 1-4. [3146104]. https://doi.org/10.1155/2021/3146104

Vancouver

McCutcheon K, Vanhaverbeke M, Dabin J, Pauwels R, Schoonjans W, Desmet W et al. Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation. Journal of Interventional Cardiology. 2021 Dec 14;2021:1-4. 3146104. https://doi.org/10.1155/2021/3146104

Author

McCutcheon, Keir ; Vanhaverbeke, Maarten ; Dabin, Jérémie ; Pauwels, Ruben ; Schoonjans, Werner ; Desmet, Walter ; Bennett, Johan. / Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation. In: Journal of Interventional Cardiology. 2021 ; Vol. 2021. pp. 1-4.

Bibtex - Download

@article{0aefacf4facc44f1b2628c48e73e5149,
title = "Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation",
abstract = "Background: The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods: We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (muSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results: The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00-29.47) muSv in the drape group versus 41.8 (IQR 30.82-60.59) muSv in the no drape group; P < 0.001) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5-5.4) E/DAPx10(-3) in the drape group versus 8.6 (IQR 4.2-12.5) E/DAPx10(-3) in the no drape group; P=0.001). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI (P value for interaction 0.963). Conclusions: The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose.",
keywords = "Interventional cardiology, Extremity dosimetry, Occupational exposure, Lead drape",
author = "Keir McCutcheon and Maarten Vanhaverbeke and J{\'e}r{\'e}mie Dabin and Ruben Pauwels and Werner Schoonjans and Walter Desmet and Johan Bennett",
note = "Score=10",
year = "2021",
month = dec,
day = "14",
doi = "10.1155/2021/3146104",
language = "English",
volume = "2021",
pages = "1--4",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Hindawi",

}

RIS - Download

TY - JOUR

T1 - Efficacy of MAVIG X-Ray Protective Drapes in Reducing CTO Operator Radiation

AU - McCutcheon, Keir

AU - Vanhaverbeke, Maarten

AU - Dabin, Jérémie

AU - Pauwels, Ruben

AU - Schoonjans, Werner

AU - Desmet, Walter

AU - Bennett, Johan

N1 - Score=10

PY - 2021/12/14

Y1 - 2021/12/14

N2 - Background: The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods: We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (muSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results: The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00-29.47) muSv in the drape group versus 41.8 (IQR 30.82-60.59) muSv in the no drape group; P < 0.001) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5-5.4) E/DAPx10(-3) in the drape group versus 8.6 (IQR 4.2-12.5) E/DAPx10(-3) in the no drape group; P=0.001). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI (P value for interaction 0.963). Conclusions: The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose.

AB - Background: The MAVIG X-ray protective drape (MXPD) has been shown to reduce operator radiation dose during percutaneous coronary interventions (PCI). Whether MXPDs are also effective in reducing operator radiation during chronic total occlusion (CTO) PCI, often with dual access, is unknown. Methods: We performed a prospective, randomized-controlled study comparing operator radiation dose during CTO PCI (n = 60) with or without pelvic MXPDs. The primary outcomes were the difference in first operator radiation dose (muSv) and relative dose of the first operator (radiation dose normalized for dose area product) at the level of the chest in the two groups. The effectiveness of MXPD in CTO PCI was compared with non-CTO PCI using a patient-level pooled analysis with a previously published non-CTO PCI randomized study. Results: The use of the MXPD was associated with a 37% reduction in operator dose (weighted median dose 26.0 (IQR 10.00-29.47) muSv in the drape group versus 41.8 (IQR 30.82-60.59) muSv in the no drape group; P < 0.001) and a 60% reduction in relative operator dose (median dose 3.5 (IQR 2.5-5.4) E/DAPx10(-3) in the drape group versus 8.6 (IQR 4.2-12.5) E/DAPx10(-3) in the no drape group; P=0.001). MXPD was equally effective in reducing operator dose in CTO PCI compared with non-CTO PCI (P value for interaction 0.963). Conclusions: The pelvic MAVIG X-ray protective drape significantly reduced CTO operator radiation dose.

KW - Interventional cardiology

KW - Extremity dosimetry

KW - Occupational exposure

KW - Lead drape

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/47944894

U2 - 10.1155/2021/3146104

DO - 10.1155/2021/3146104

M3 - Article

VL - 2021

SP - 1

EP - 4

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

M1 - 3146104

ER -

ID: 7393626